Perspectives for the development of human papillomavirus vaccines and immunotherapy

References

• IARC Handbooks of Cancer Prevention (Volume 10): Cervix Cancer Screening. IARC Press, Lyon, France (2005).
   Google Scholar
• zur Hausen H. Papillomavirus infections – a major cause of human cancers. Biochim. Biophys. Acta1288(2), F55–F78 (1996).
   PubMed Web of Science ®Google Scholar
• Hines JF, Ghim SJ, Christensen ND et al. Role of conformational epitopes expressed by human PV major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol. Oncol.55, 13–20 (1994).
   PubMedGoogle Scholar
• Culp TD, Spatz CM, Reed CA, Christensen ND. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology361, 435–446 (2007).
   PubMed Web of Science ®Google Scholar
• Brinkman J, Hughes S, Stone P et al. Therapeutic vaccination for HPV induced cervical cancers. Dis. Markers23, 337–352 (2007).
   PubMed Web of Science ®Google Scholar
• Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nat. Rev. Immunol.4, 46–55 (2004).
   PubMed Web of Science ®Google Scholar
• Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect. Dis.3, 469–475 (2003).
   PubMed Web of Science ®Google Scholar
• Schneider A, Gissmann L. Cervical cancer. The potential role of human papillomavirus (HPV)-specific vaccines in prevention and treatment. Am. J. Cancer2, 1–253 (2003).
   Google Scholar
• Schiller JT, Castellsagué X, Villa LL, Hildesheim A. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine19(Suppl. 10), K53–K61 (2008).
   Google Scholar
• Belot A, Grosclaude P, Bossard N et al. Cancer incidence and mortality in France over the period 1980–2005. Rev. Epidemiol. Sante Publique56, 159–175 (2008).
   PubMed Web of Science ®Google Scholar
• Patnick J. Review of recommendations on cervical cancer screening in the European Union. Minerva Ginecol.55, 293–295 (2003).
   PubMedGoogle Scholar
• Weinstein LC, Buchanan EM, Hillson C, Chambers CV. Screening and prevention: cervical cancer. Prim. Care36, 559–574 (2009).
   PubMedGoogle Scholar
• Anttila A, von Karsa L, Aasmaa A et al. Cervical cancer screening policies and coverage in Europe. Eur. J. Cancer45(15), 2649–2658 (2009)
   PubMed Web of Science ®Google Scholar
• Koulova A, Tsui J, Irwin K, Van Damme P, Biellik R, Aguado MT. Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006–January 2008. Vaccine2, 6529–6541 (2008).
   Google Scholar
• Bergeron C, Breugelmans JG, Bouée S, Lorans C, Bénard S, Rémy V. Cervical cancer screening and associated treatment costs in France. Gynecol. Obstet. Fertil.34, 1036–1042 (2006).
   PubMedGoogle Scholar
• Hagensee ME, Yaegashi N, Galloway DA. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J. Virol.67, 315–322 (1993).
   PubMed Web of Science ®Google Scholar
• Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc. Natl Acad. Sci. USA15, 12180–12184 (1992).
   Google Scholar
• Siddiqui MA, Perry CM. Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs66, 1263–1271 (2006).
   PubMed Web of Science ®Google Scholar
• Bryan JT. Developing an HPV vaccine to prevent cervical cancer and genital warts. Vaccine20, 3001–3006 (2007).
   Google Scholar
• Schmiedeskamp MR, Kockler DR. Human papillomavirus vaccines. Ann. Pharmacother.40, 1344–1352 (2006).
   PubMed Web of Science ®Google Scholar
• Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev. Vaccines7(10), 1465–1473 (2008).
   PubMed Web of Science ®Google Scholar
• Rouzier R, Uzan C, Collinet P. HPV vaccination: principles, results and future perspectives. J. Gynecol. Obstet. Biol. Reprod. (Paris)36, 13–18 (2007).
   PubMedGoogle Scholar
• Guidance for the introduction of HPV vaccines in EU countries. European Centre for Disease Prevention and Control. Stockholm, Sweden, January (2008).
   Google Scholar
• WHO–UNICEF Joint Reporting Form and WHO Regional offices 2009, WHO Immunization surveillance, assessment, and monitoring. WHO, Geneva, Switzerland (2009).
   Google Scholar
• Castellsagué X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol .Oncol.110, S4–S7 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou J, Sun XY, Davies H, Crawford L, Park D, Frazer IH. Definition of linear antigenic regions of the HPV16 L1 capsid protein using synthetic virion-like particles. Virology189, 592–599 (1992).
   PubMed Web of Science ®Google Scholar
• Kowalczyk DW, Wlazlo AP, Shane S, Ertl HC. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. Vaccine14, 3583–3590 (2001).
   Google Scholar
• Nardelli-Haefliger D, Roden RB, Benyacoub J et al. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect. Immun.65, 3328–3336 (1997).
   PubMed Web of Science ®Google Scholar
• Jabbar IA, Fernando GJ, Saunders N et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine8, 2444–2453 (2000).
   Google Scholar
• Warzecha H, Mason HS, Lane C et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J. Virol.77(16), 8702–8711 (2003).
   PubMed Web of Science ®Google Scholar
• Cho HJ, Shin HJ, Han IK et al. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine19, 8049–8057 (2007).
   Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med.11, S45–S53 (2005).
   PubMed Web of Science ®Google Scholar
• Cesta MF. Normal structure, function and histology of mucosa-associated lymphoid tissue. Toxicol. Pathol.34, 599–608 (2006).
   PubMed Web of Science ®Google Scholar
• Corr SC, Gahan CC, Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol. Med. Microbiol.52, 2–12 (2008).
   PubMed Web of Science ®Google Scholar
• Davis SS. Nasal vaccines. Adv. Drug. Deliv. Rev.51, 21–42 (2001).
   PubMed Web of Science ®Google Scholar
• Hu KF, Lövgren-Bengtsson K, Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv. Drug. Deliv. Rev.51, 149–159 (2001).
   PubMed Web of Science ®Google Scholar
• Daudel D, Weidinger G, Spreng S. Use of attenuated bacteria as delivery vectors for DNA vaccines. Expert Rev. Vaccines6(1), 97–110 (2007).
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Alonso S, Locht C. Nasal vaccination using live bacterial vectors. Adv. Drug Deliv. Rev.51, 55–69 (2001).
   PubMed Web of Science ®Google Scholar
• Singh M, Chakrapani A, O’Hagan D et al. A comparison of anionic nanoparticles and microparticles as vaccine delivery systems. Hum. Vaccin.4, 44–49 (2008).
   PubMedGoogle Scholar
• Berg M, Difatta J, Hoiczyk E, Schlegel R, Ketner G. Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit. Proc. Natl Acad. Sci. USA22, 4590–4595 (2005).
   Google Scholar
• Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology187, 612–619 (1992).
   PubMed Web of Science ®Google Scholar
• Reuter JD, Vivas-Gonzalez BE, Gomez D et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J. Virol.76, 8900–8909; erratum in: J. Virol.77, 2799 (2002).
   PubMedGoogle Scholar
• Roberts A, Reuter JD, Wilson JH, Baldwin S, Rose JK. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J. Virol.78, 3196–9 (2004).
   PubMed Web of Science ®Google Scholar
• Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nat. Rev. Microbiol.6, 349–362 (2008).
   PubMed Web of Science ®Google Scholar
• Fraillery D, Baud D, Pang SY et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin. Vaccine Immunol.14, 1285–1295 (2007).
   PubMed Web of Science ®Google Scholar
• Bermúdez-Humarán LG, Corthier G, Langella P. Recent advances in the use of Lactococcus lactis as live recombinant vector for the development of new safe mucosal vaccines. Recent Res. Devel. Microbiol.8, 147–160 (2004).
   Google Scholar
• Bermúdez-Humarán LG. Lactococcus lactis as a live vector for mucosal delivery of therapeutic proteins. Hum. Vaccin.5, 264–267 (2009).
   PubMed Web of Science ®Google Scholar
• Aires KA, Cianciarullo AM, Carneiro SM et al. Production of human papillomavirus type 16 L1 virus like particles by recombinant Lactobacillus casei cells. Appl. Environ. Microbiol.72, 745–752 (2006).
   PubMedGoogle Scholar
• Cortes-Perez NG, Kharrat P, Langella P, Bermúdez-Humarán LG. Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium. BMC Res. Notes24, 167 (2009).
   Google Scholar
• Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum. Pathol.35, 971–982 (2004).
   PubMed Web of Science ®Google Scholar
• Christensen ND, Kreider JW, Kan NC, DiAngelo SL. The open reading frame L2 of cottontail rabbit papillomavirus contains antibody inducing neutralizing epitopes. Virology181, 572–579 (1991).
   PubMed Web of Science ®Google Scholar
• Lin YL, Borenstein LA, Selvakumar R, Ahmed R, Wettstein FO. Effective vaccination against papilloma development by immunization with L1 or L2 structural protein of cottontail rabbit papillomavirus. Virology187, 612–619 (1992).
   PubMed Web of Science ®Google Scholar
• Thompson HS, Davies ML, Holding FP et al. Phase I safety and antigenicity of TA-GW: a recombinant HPV6 L2E7 vaccine for the treatment of genital warts. Vaccine17, 40–49 (1999).
   PubMed Web of Science ®Google Scholar
• Monie A, Hung CF, Wu TC. Preventive and therapeutic HPV vaccines. Curr. Opin. Investig. Drugs8, 1038–1050 (2007).
   PubMedGoogle Scholar
• Corona-Gutierrez CM, Tinoco A, Navarro T et al. Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus. Hum. Gene Ther.15, 421–431 (2004).
   PubMedGoogle Scholar
• Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol.23, 2242–2249 (1993).
   PubMed Web of Science ®Google Scholar
• Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J. Immunol.169, 350–358 (2002).
   PubMed Web of Science ®Google Scholar
• Tindle RW, Croft S, Herd K et al. A vaccine conjugate of ‘ISCAR’ immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin. Exp. Immunol.101, 265–271 (1995).
   PubMedGoogle Scholar
• Muderspach L, Wilczynski S, Roman L et al. A Phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. Clin. Cancer Res.6, 3406–3416 (2000).
   PubMed Web of Science ®Google Scholar
• Steller MA, Gurski KJ, Murakami M et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. Clin. Cancer Res.4, 2103–2109 (1998).
   PubMed Web of Science ®Google Scholar
• Hariharan K, Braslawsky G, Barnett RS et al. Tumor regression in mice following vaccination with human papillomavirus E7 recombinant protein in PROVAX. Int. J. Oncol.12, 1229–1235 (1998).
   PubMed Web of Science ®Google Scholar
• Ahn WS, Bae SM, Kim TY et al. A therapy modality using recombinant IL-12 adenovirus plus E7 protein in a human papillomavirus 16 E6/E7-associated cervical cancer animal model. Hum. Gene Ther.10, 1389–1399 (2003).
   Google Scholar
• Liu B, Ye D, Song X et al. A novel therapeutic fusion protein vaccine by two different families of heat shock proteins linked with HPV16 E7 generates potent antitumor immunity and antiangiogenesis. Vaccine4, 1387–1396 (2008).
   Google Scholar
• Préville X, Ladant D, Timmerman B, Leclerc C. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Cancer Res.15, 641–649 (2005).
   Google Scholar
• van der Burg SH, Kwappenberg KM, O’Neill T et al. Pre-clinical safety and efficacy of TA–CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime–boost regimens. Vaccine14, 3652–3660 (2001).
   Google Scholar
• de Jong A, O’Neill T, Khan AY et al. Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. Vaccine4, 3456–3464 (2002).
   Google Scholar
• Hunt S. Technology evaluation: HspE7, StressGen Biotechnologies Corp. Curr. Opin. Mol. Ther.3, 413–417 (2001).
   PubMedGoogle Scholar
• Einstein MH, Kadish AS, Burk RD et al. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. Gynecol. Oncol.106, 453–460 (2007).
   PubMed Web of Science ®Google Scholar
• Rice J, Ottensmeier CH, Stevenson FK. DNA vaccines: precision tools for activating effective immunity against cancer. Nat. Rev. Cancer8, 108–120 (2008).
   PubMed Web of Science ®Google Scholar
• Monie A, Tsen SW, Hung CF, Wu TC. Therapeutic HPV DNA vaccines. Expert Rev. Vaccines8, 1221–1235 (2009).
   PubMed Web of Science ®Google Scholar
• Brulet JM, Maudoux F, Thomas S et al. DNA vaccine encoding endosome-targeted human papillomavirus type 16 E7 protein generates CD4+ T cell-dependent protection. Eur. J. Immunol.7, 376–384 (2007).
   Google Scholar
• Kang TH, Lee JH, Bae HC et al. Enhancement of dendritic cell-based vaccine potency by targeting antigen to endosomal/lysosomal compartments. Immunol. Lett.15, 126–134 (2006).
   Google Scholar
• Hung CF, Yang M, Wu TC. Modifying professional antigen-presenting cells to enhance DNA vaccine potency. Methods Mol. Med.127, 199–220 (2006).
   PubMedGoogle Scholar
• Hsieh CY, Chen CA, Huang CY et al. IL-6-encoding tumor antigen generates potent cancer immunotherapy through antigen processing and anti-apoptotic pathways. Mol. Ther. Oct.15, 1890–1897 (2007).
   PubMedGoogle Scholar
• Tommasino M, Jansen-Durr P. E7 protein. In: Papillomaviruses in Human Cancer: the Role of E6 and E7 Oncoproteins. Tommasino M (Ed.). Landes Bioscience, Austin, TX, USA, 103–136 (1997).
   Google Scholar
• Kaufmann AM, Stern PL, Rankin EM et al. Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. Clin. Cancer Res.8, 3676–3685 (2002).
   PubMed Web of Science ®Google Scholar
• Daemen T, Riezebos-Brilman A, Bungener L, Regts J, Dontje B, Wilschut J. Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7. Vaccine7, 1082–1088 (2003).
   Google Scholar
• Cassetti MC, McElhiney SP, Shahabi V et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine2, 520–527 (2004).
   Google Scholar
• Brandsma JL, Shlyankevich M, Zhang L et al. Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to clearance of papillomas and infection. J. Virol.78, 116–123 (2004).
   PubMed Web of Science ®Google Scholar
• Brandsma JL, Shylankevich M, Su Y et al. Vesicular stomatitis virus-based therapeutic vaccination targeted to the E1, E2, E6, and E7 proteins of cottontail rabbit papillomavirus. J. Virol.81, 5749–5758 (2007).
   PubMed Web of Science ®Google Scholar
• Kanodia S, Da Silva DM, Kast WM. Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions. Int. J. Cancer15, 247–259 (2008).
   Google Scholar
• Hussain SF, Paterson Y. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors. Cancer Immunol. Immunother.54, 577–586 (2005).
   PubMed Web of Science ®Google Scholar
• Gregory SH, Liu CC. CD8+ T-cell-mediated response to Listeria monocytogenes taken up in the liver and replicating within hepatocytes. Immunol. Rev.174, 112–122 (2000).
   PubMed Web of Science ®Google Scholar
• Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol.167, 6471–6479 (2001).
   PubMed Web of Science ®Google Scholar
• Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm–LLO–E7 in patients with advanced carcinoma of the cervix. Vaccine19, 3975–3983 (2009).
   Google Scholar
• Bermúdez-Humarán LG, Langella P, Cortes-Perez NG et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect. Immun.71, 1887–1896 (2003).
   PubMed Web of Science ®Google Scholar
• Bermúdez-Humarán LG, Cortes-Perez NG, Lefevre F et al. A novel mucosal vaccine based on live lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors. J. Immunol.175, 7297–7302 (2005).
   PubMed Web of Science ®Google Scholar